Mises à jour récentes
-
Gefitinib: Treatment for EGFR-Mutated Non-Small Cell Lung CancerLung cancer remains one of the most prevalent and deadly cancers worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases. Among NSCLC patients, mutations in the epidermal growth factor receptor (EGFR) gene have been identified as a key driver of tumor growth. Gefitinib, an oral tyrosine kinase inhibitor (TKI), has emerged as a revolutionary treatment for...0 Commentaires 0 Parts 46 Vue 0 AperçuConnectez-vous pour aimer, partager et commenter!
-
0 Commentaires 0 Parts 58 Vue 0 Aperçu
Plus de lecture